Clinical Trials Logo
  1. Home
  2. Carcinoma, Small Cell Lung
  3. NCT04622228

Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer — Match  

Carcinoma, Small Cell Lung Clinical Trial

Official title:
Phase II, Single-Arm Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

Clinical Trial Summary

This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with atezolizumab in participants who have extensive-stage small cell lung cancer (ES-SCLC) and are chemotherapy-navïe for their extensive-stage disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04622228
Study type Interventional
Source Hoffmann-La Roche
Contact
Status Active, not recruiting
Phase Phase 2
Start date December 16, 2020
Completion date June 30, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT00037713 - Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG Phase 3
Recruiting NCT02736916 - HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer N/A
Terminated NCT00637624 - N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy N/A
Completed NCT00308529 - Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer Phase 2
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Active, not recruiting NCT01306045 - Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Phase 2
Terminated NCT00435578 - Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma Phase 2
Completed NCT00294931 - Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Phase 2
Terminated NCT00265200 - Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer Phase 2
Completed NCT00270166 - The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy Phase 3
Completed NCT02936323 - PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Phase 1/Phase 2
Terminated NCT03699956 - RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer Phase 3
Completed NCT00263731 - Metabolomic Analysis of Lung Cancer
Recruiting NCT04253145 - Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. Phase 1/Phase 2
Terminated NCT04308785 - A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05566041 - A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer Phase 3
Completed NCT03083691 - BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer Phase 2
Not yet recruiting NCT03871205 - Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer Phase 1